Ahmed Khalid Mohammed, Huda I. Al-Qadhi, Nawal Mehdi Alkhalidi, Hayder Adnan Fawzi

Abstract

Background: Ulcerative colitis can affect the quality of life and in some cases can cause life-threatening complications. Biologic drugs such as Infliximab (IFX) and Adalimumab (ADA) are anti-TNF-α, administered to patients for reducing colonic inflammation. This study aimed to evaluate the effect of IFX and ADA ‎in patients with ulcerative colitis. Methods: One hundred patients who had previously diagnosed with UC at least 3 months had received treatment protocols prescribed by physicians in the GIT center and had received biological treatment (all patients received no previous TNF inhibitor). The patients were divided into two groups; The first group (70 UC patients) received Infliximab and the second group (30 UC patients) received Adalimumab. All patients were followed up for 6 months after the onset of biological agents. Results: The study included 100 UC patients, at baseline 45% of patients with endoscopy subscore 1, after 6 months only 26 of them (57.8%) remained with the same score, also 18 of them (40%) lowering their score to zero, only one patient had increased to three. Initially, 55% of patients had endoscopy subscore 2 and 3, after 6 months only 3 of them remained with the same score, the rest of them reduces at least one level. Infliximab showed slightly better conversion from moderate-severe Mayo endoscopic sub-score to mucosal healing (MH), 97.3%, compared to adalimumab (83.3%), but the difference between the two drugs was not significant. Conclusions: In this Real-World study, there was no significant difference between the most commonly used anti-TNF medications in the treatment of UC, namely infliximab and adalimumab, in their effect on reducing relapse rate and mucosal healing after 6 months follow-up‎.